Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis

Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis

Jun 19, 2018
Source URL: https://qa1.novartis.us/news/media-releases/novartis-receives-fda-approval-inclusion-new-evidence-cosentyx-inhibits-progression-joint-structural-damage-psoriatic-arthritis-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-receives-fda-approval-inclusion-new-evidence-cosentyx-inhibits-progression-joint-structural-damage-psoriatic-arthritis-0